BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

4:58 PM
 | 
Aug 05, 2009
 |  BC Extra  |  Clinical News

BA058 meets osteoporosis endpoints

Radius Health Inc. (Cambridge, Mass.) said top-line data showed that 80 ug/day subcutaneous BA058 met the co-primary endpoints in a Phase II trial to treat osteoporosis in postmenopausal women. The co-primary endpoints of the...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >